Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.57), $0.01 worse than the analyst estimate of ($1.56). Revenue for the quarter came in at $139 million versus the consensus estimate of $145.39 million.

GUIDANCE:

Ultragenyx Pharma sees FY2025 revenue of $640-670 million, versus the consensus of $655.8 million.

Crysvita revenue to be in the range of $460 million to $480 million
Dojolvi revenue to be in the range of $90 million to $100 million

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.